Biopharma Dealmaking Quarterly Statistics, Q3 2012
A look at financing, M&A, and alliance activity July-September 2012
Executive Summary
Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.
You may also be interested in...
MacroGenics Strikes Second Oncology Partnership With Servier
The French pharma paid $20 million up-front for rights to option three preclinical programs, including drugs targeting both solid and liquid-tumor cancers.
Financings Of The Fortnight Notices Autumn Coincides With Increase In Option Deals
Plus news on recent financings by MyoKardia, Biogen Idec, Annovation and Wellington Partners.
Third Rock Ventures Pumps $38 Million Into New Firm Focused On Genetic Heart Disease
Third Rock is the sole Series A investor in MyoKardia, which plans to use personalized medicine to treat hypertrophic and dilated cardiomyopathies.